By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences said on Monday that it has entered into a drug screening deal with the Moulder Center for Drug Discovery Research at Temple University.

The multi-year agreement calls for GVK Bio to validate targets and identify and optimize small molecules in specific therapeutic areas, such as cardiovascular, metabolic, and central nervous system disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.